Comparison of two methacholine challenge methods using Spira‐2 or Mefar dosimeter

Jõgi, Rain; Janson, Christer; Hedenström, Hans

doi:10.1046/j.1365-2281.1999.00181.x

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standardization of protocols is necessary to produce comparable results between provocative agents and methods (8)(9)(10)(11). For that purpose the European Respiratory Society (ERS) (7) and the American Thoracic Society (ATS) (1 ) guidelines for BHR testing have made a serious attempt to integrate the variety of tools for measuring BHR.…”

Section: Introductionmentioning

confidence: 99%

Bronchial hyperresponsiveness in a population of north Finland with no previous diagnosis of asthma or chronic bronchitis assessed with histamine and methacholine tests

Juusela

Poussa

Kotaniemi

et al. 2008

International Journal of Circumpolar Health

View full text Add to dashboard Cite

Objectives. To assess the prevalence of bronchial hyperresponsiveness (BHR) in a population of north Finland among subjects with no previous diagnosis of asthma or chronic bronchitis by using histamine and methacholine challenges. The agreement between the methods was also evaluated. Study design. An epidemiological study assessing the prevalence of BHR measured with direct dosimetric challenge methods. Methods. Seventy-nine randomly selected subjects ( 1-73 years) were studied; 67% had respiratory or allergic symptoms. The baseline spirometry was normal or showed mild obstruction. Bronchial challenges to methacholine and histamine were performed on each subject in a randomized order. Provocative doses inducing the decrease of FEV 1 by 15% and 0% (PD 15 FEV 1 and PD 0 FEV 1 ) and dose response ratios (DDR) were calculated for both tests. Results. BHR with the methacholine test (PD 0 FEV 1 ≤2.6 mg) was found in 20% and with the histamine test (PD 15 FEV 1 ≤1.6 mg) in 28% of subjects; the agreement was 80% (kappa 0.45; 95% CI 0. 3-0.68). In staging the severity of BHR the methods had a good agreement (weighted kappa 0.64; CI 95% 0.46-0.82). Prevalence of BHR fulfilling the criteria of the both methods was 14%. Conclusions. The findings suggest that the prevalence of BHR in the population of north Finland with no previous diagnosis of asthma or chronic bronchitis is at least 14%, probably around 0%, assessed by histamine and methacholine challenge methods. The methods have a good agreement to be used for classifying the severity of BHR. (Int J Circumpolar Health 2008; 67(4):308-317)

show abstract

Section: Introductionmentioning

confidence: 99%

Bronchial hyperresponsiveness in a population of north Finland with no previous diagnosis of asthma or chronic bronchitis assessed with histamine and methacholine tests

Juusela

Poussa

Kotaniemi

et al. 2008

International Journal of Circumpolar Health

View full text Add to dashboard Cite

show abstract

“…Apparently, well-standardized dosimeter methods may differ in dose-response slopes, so that correction factors have been suggested (Jõgi et al, 1999). In a previous study (Schulze et al, 2009), ATS standard five-step protocol was compared with a single concentration dosimetric technique utilizing the APS system in the assessment of bronchial hyperresponsiveness in 52 young adults.…”

Section: Discussionmentioning

confidence: 99%

Standardizing dose in dosimetric bronchial challenge tests

Malmberg

Kauppi

Mäkelä

2018

Clin Physio Funct Imaging

View full text Add to dashboard Cite

Recent technical recommendations on bronchial challenge testing aim at standardized assessment of provocative dose of causing 20% decrease in FEV1 (PD20). The aim of this study was to investigate the effect of mode of nebulization on the output of a computerized dosimeter (APS) and to compare PD20 obtained by two different dosimetric systems in vivo. The output of the APS system was tested during continuous nebulization, and using simulated breaths, for intermittent actuations with four different durations. Using output data, a modified methacholine challenge protocol was applied for APS and compared with a standard set-up using Spira dosimeter in 14 asthmatic patients attending duplicate methacholine challenges using both systems, within median (range) 3 (1-6) days apart. The calculated output (mg min ) with all the intermittent mode settings was significantly higher (P<0·001) than in the continuous mode, and in the intermittent mode, the output was dependent of the pulse duration. The PD20 values assessed with the APS and Spira systems were significantly correlated (r = 0·69; P<0·007), without systematic difference in the geometric means (P = 0·10). A moderate to good agreement was found for assessment of significant hyperresponsiveness. The results suggest that in dosimetric systems for bronchial challenge tests, the output of the nebulizer is dependent on the mode of nebulization, and this should be considered when standardizing the dose between devices and protocols. As long as the delivered dose is determined for the specified nebulization mode of the protocol, it may be possible to obtain comparable results between different devices.

show abstract

Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration

Brülls

Oag²,

Karlsson³

et al. 2022

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Comparison of two methacholine challenge methods using Spira‐2 or Mefar dosimeter

Cited by 3 publications

References 13 publications

Bronchial hyperresponsiveness in a population of north Finland with no previous diagnosis of asthma or chronic bronchitis assessed with histamine and methacholine tests

Bronchial hyperresponsiveness in a population of north Finland with no previous diagnosis of asthma or chronic bronchitis assessed with histamine and methacholine tests

Standardizing dose in dosimetric bronchial challenge tests

Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration

Contact Info

Product

Resources

About